GSK and Verily Life Sciences form new joint venture Galvani Bioelectronics
GlaxoSmithKline PLC and Verily Life Sciences LLC formed a new joint venture company Galvani Bioelectronics focusing on bioelectronic medicines. The two parent companies will contribute existing IP rights and invest up to £540mm ($702mm) over a seven-year term (subject to completion of discovery and development milestones).
- Medical Devices
- Implantable Devices
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Drug Discovery Technologies
- Nanotechnology, Chips, etc.
- Includes Equity
- Joint Venture
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.